Bambusa Therapeutics IPO: offering terms from its S-1
Bambusa Therapeutics filed its S-1 on 9 Oct 2026 to list on Nasdaq as BBTX, and has amended it once. It set a price range of $15-$17 a share.
Headlines
- Net loss, 2025
- $41M
- Price range
- $15-$17
- $150M at the midpoint
Bambusa Therapeutics IPO terms
From the newest registration statement. Terms left blank there are not set yet.
- Exchange
- Nasdaq Global Select Market
- Ticker
- BBTX
- Price range
- $15-$17
- Shares offered
- 9,375,000
- Expected to raise
- $150M at the midpoint
- Registered
- $183M, the amount the filing fee is paid on
- Underwriters
- BofA Securities, Evercore ISI, UBS Investment Bank and Cantor
- First filed
- 9 Oct 2026
Bambusa Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$44M | -$41M |
| First half of 2026 | - | -$24M | -$22M |
Bambusa Therapeutics share structure and company facts
- Employees
- 30
- Headquarters
- Boston, Massachusetts
Bambusa Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Bambusa Therapeutics' newest prospectus (S-1/A filed 26 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.